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Abstract
Background: Genetic variations in apolipoprotein E (APOE) and proximal genes (PVRL2, TOMM40, and APOC1) are
associated with cognitive function and dementia, particularly Alzheimer’s disease. Epigenetic mechanisms such as
DNA methylation play a central role in the regulation of gene expression. Recent studies have found evidence that
DNA methylation may contribute to the pathogenesis of dementia, but its association with cognitive function in
populations without dementia remains unclear.
Methods: We assessed DNA methylation levels of 48 CpG sites in the APOE genomic region in peripheral blood
leukocytes collected from 289 African Americans (mean age = 67 years) from the Genetic Epidemiology Network
of Arteriopathy (GENOA) study. Using linear regression, we examined the relationship between methylation in the
APOE genomic region and multiple cognitive measures including learning, memory, processing speed,
concentration, language and global cognitive function.
Results: We identified eight CpG sites in three genes (PVRL2, TOMM40, and APOE) that showed an inverse
association between methylation level and delayed recall, a measure of memory, after adjusting for age and sex
(False Discovery Rate q-value < 0.1). All eight CpGs are located in either CpG islands (CGIs) or CGI shelves, and
six of them are in promoter regions. Education and APOE ε4 carrier status significantly modified the effect of
methylation in cg08583001 (PVRL2) and cg22024783 (TOMM40), respectively. Together, methylation of the eight
CpGs explained an additional 8.7% of the variance in delayed recall, after adjustment for age, sex, education, and
APOE ε4 carrier status. Methylation was not significantly associated with any other cognitive measures.
Conclusions: Our results suggest that methylation levels at multiple CpGs in the APOE genomic region are
inversely associated with delayed recall during normal cognitive aging, even after accounting for known genetic
predictors for cognition. Our findings highlight the important role of epigenetic mechanisms in influencing
cognitive performance, and suggest that changes in blood methylation may be an early indicator of individuals
at risk for dementia as well as potential targets for intervention in asymptomatic populations.
Keywords: DNA methylation, Epigenetics, Cognition, Cognitive function, Delayed recall, Memory, Apolipoprotein E
* Correspondence: smjenn@umich.edu
1Department of Epidemiology, School of Public Health, University of
Michigan, 1415 Washington Heights, 4602 SPH Tower, Ann Arbor, MI
48109-2029, USA
2Survey Research Center, Institute for Social Research, University of Michigan,
Ann Arbor, MI 48104, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. BMC Medical Genomics  (2018) 11:43 
https://doi.org/10.1186/s12920-018-0363-9
Background
Apolipoprotein E (apoE) plays an essential role in lipid
metabolism, and variability in this protein influences
several lipid-related diseases of older age, including
coronary heart disease, stroke, and Alzheimer’s disease
(AD) [1]. ApoE also likely influences AD through other
biologic mechanisms, including amyloid-β aggregation
[2]. The APOE ε4 allele has been identified as the most
robust genetic risk factor for AD and age-related cog-
nitive impairment in multiple populations including
African Americans [3]. In addition to the ε4 allele,
other genetic variations in APOE and genes in close
genomic proximity, such as TOMM40, PVRL2, and
APOC1, are also associated with cognition [4–10] and
may contribute to the pathogenesis of age-related cog-
nitive impairment.
Cognition and AD risk may be influenced not only by
the DNA sequence but also by epigenetic profiles in the
APOE region. Epigenetic mechanisms, such as histone
modification, DNA methylation, and non-coding RNA
can regulate gene expression while the underlying DNA
sequence remains the same. The epigenome is influenced
both by underlying genetic variants as well as by environ-
mental factors including the social environment, health
behaviors, and environmental pollutants [11]. Methylation
of CpG dinucleotides, the best understood epigenetic
mechanism, is also dynamic over the life course. It is well
established that epigenomic patterns of DNA methylation
change with age [12]. A recent study in lymphocytes
showed that methylation levels at several CpG sites in
APOE were significantly associated with age, and that
these age-related changes in methylation were modified
by APOE genetic variants [13].
Methylation levels at CpG sites in APOE have also
been associated with AD or its underlying pathology in
the brain. For example, decreased methylation was ob-
served in the CpG island (CGI) nested within the
fourth exon of APOE in brain tissue from AD cases
compared to controls [14]. This differential methylation
was only observed in brain regions known to impact
AD pathophysiology (frontal lobe and hippocampus),
suggesting that APOE methylation may play a role in
AD pathogenesis. Further, in postmortem brain tissue,
a significant positive association was found between
methylation at a separate site within APOE exon 4 and
neuritic amyloid plaque burden, the primary subclinical
biomarker of AD pathology [15]. Although these previ-
ous studies have explored the relationship between
APOE methylation and AD, there are still many un-
answered questions about the mechanistic actions of
APOE methylation and its influences on disease. Add-
itionally, the majority of previous epigenetic studies
have focused on participants with European or Asian an-
cestry [12]. To our knowledge, no study has investigated
the association between APOE methylation and cognitive
function in older African Americans without clinically-
diagnosed dementia.
In this study, we investigate the association between
peripheral blood leukocyte methylation levels in the
APOE genomic region (APOE, TOMM40, PVRL2, and
APOC1) and cognitive function in 289 African American
participants from the Genetic Epidemiology Network of
Arteriopathy (GENOA) study. We also assess whether
education and the presence of the APOE ε4 allele con-
found and/or modify the association between methyla-
tion and cognitive function. Deeper insight into the
epigenetic mechanisms that influence cognitive function
may facilitate improved risk assessment, earlier interven-
tion, and more effective treatment for AD and cognitive
decline in the era of precision medicine.
Methods
Study sample
Study participants are African Americans from the Genetic
Epidemiology Network of Arteriopathy (GENOA) study, a
community-based study of hypertensive sibships designed
to investigate the genetics of hypertension and target organ
damage in African Americans from Jackson, Mississippi,
and non-Hispanic Whites from Rochester, MN [16, 17]. In
the initial phase of GENOA (Phase I: 1996–2001), all
members of sibships containing ≥2 individuals with essen-
tial hypertension clinically diagnosed before age 60 were
invited to participate, including both hypertensive and
normotensive siblings. Eighty percent of African Ameri-
cans (N = 1482) from the initial study population returned
for the second examination (Phase II: 2001–2005).
Hypertension was defined as having systolic blood pres-
sure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg,
or previous diagnosis of hypertension and use of anti-
hypertensive medication. Diabetes was defined as
fasting blood glucose ≥126 mg/dL or use of antidiabetic
medication. Body mass index (BMI, kg/m2) was
calculated from measured weight and height. A subset
of participants also had measures of cerebral white
matter hyperintensity (WMH). WMH was assessed by
Magnetic Resonance Imaging (MRI), and transformed as
ln(WMH+ 1) to reduce skewness. In an ancillary study
(2001–2006), a total of 1010 African American GENOA
participants completed a battery of established cognitive
tests that assessed five domains including memory,
learning, processing speed, language, and concentration.
DNA methylation levels were measured from blood
samples collected at Phase I for 422 unrelated participants.
Of those with DNA methylation, 289 had at least one
cognitive measure and had never been diagnosed with
dementia by a physician, and a smaller subset (N = 247)
also had genotype data available for analysis.
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Cognitive function measures
Six measures of cognitive function were evaluated [18]:
(1) the Wechsler Adult Intelligence Scale Revised Digit
Symbol Substitution Task (DSST) assessed processing
speed, complex visual attention and visuomotor coordin-
ation, (2) the Controlled Oral Word Association Test
(COWA, Animal Naming) assessed category fluency, (3)
the COWA (FAS) assessed letter fluency, (4) the Rey
Auditory Verbal Learning Test (RAVLT) immediate mem-
ory trial assessed learning ability, (5) the RAVLT delayed
memory trial assessed delayed recall, and (6) the Stroop
Color and Word Test (SCWT) assessed concentration ef-
fectiveness. For additional details, see Smith et al. [19].
Since global cognitive function is an important indica-
tor of health in older age, reflecting an on-the-spot in-
formation processing function employed across various
cognitive domains [20], we created a measure of global
cognitive function using principal component analysis
(PCA) in the sample of GENOA African Americans
(N = 1010) with cognitive data. The global cognitive
function factor was defined as the first unrotated prin-
cipal component from PCA using the covariance struc-
ture of the six cognitive measures described above. This
factor explained 53% of the total variance of the six cogni-
tive measures, and was well loaded by all six measures
(loading values ranged from 0.63 to 0.80).
DNA methylation measures
DNA methylation was measured using peripheral blood
leukocytes from stored blood samples collected during
Phase I. The methylation assay was performed at the
Mayo Clinic Advanced Genomics Technology Center
using the Illumina Infinium HumanMethylation450 Bead-
Chip. The Minfi R package [21] was used to preprocess
and normalize the data using the SWAN method [22]. β-
values for each CpG site were calculated as β =max(M,0)/
[(max(U,0) +max(M,0) + 100], where M represents the
fluorescence intensity of the methylated sites and U repre-
sents the fluorescence intensity of the unmethylated sites.
Individual samples and CpG sites with a high missing rate
(> 5%) were excluded. The proportion of each white blood
cell type was estimated using Houseman’s method [23].
For each CpG site, the methylation level used for analysis
was defined as the β-value multiplied by 100 (described as
a percentage of methylation), adjusted for batch effects
and white blood cell proportions. β-values greater than
four standard deviations from the mean of each CpG site
were excluded. Forty-eight CpG sites in the PVRL2-
TOMM40-APOE-APOC1 genomic region were analyzed.
We used Illumina annotation [24] to determine whether
each CpG site was in a promoter region (within 1.5 kb be-
fore the transcription start site of a gene) and/or a CGI,
CGI shore (0–2 kb from CGI), or CGI shelf (2-4 kb
from CGI).
Genotype measures
We assessed the presence of the APOE ε2 and ε4 al-
leles in a subset of participants with available genotype
data (N = 247) to evaluate potential confounding and/
or effect modification by APOE genotype. DNA was
isolated using the PureGene DNA Isolation Kit from
Gentra Systems (Minneapolis MN). Genotyping, based
on polymerase chain reaction amplification techniques,
was conducted at the University of Texas-Health Sciences
Center at Houston using the TaqMan assay and ABI
Prism® Sequence Detection System (Applied Biosystems,
Foster City CA). Participants were classified as ε2 carriers
(having at least one copy of ε2 allele) vs. non-carriers, and
ε4 carriers vs. non-carriers.
Statistical analysis
All statistical analyses were performed in SAS version
9.4 (Cary, NC) and RStudio [25]. Characteristics of the
full analysis sample (N = 289) and the subset sample
with genotype data (N = 247) were compared using T-
tests for continuous variables or χ 2 tests for categorical
variables.
The primary analysis was conducted in the full analysis
sample (N = 289). Linear regression was used to test for
association between the methylation level of each CpG
site and each cognitive measure, adjusting for sex and
age at cognitive testing (Model 1). A second set of
models also included education (less than high school
degree, high school degree/GED, beyond high school de-
gree) (Model 2). We assessed models with and without
education because adjustment for education can poten-
tially mask the effect of inherited factors on cognition, if
they also influence educational attainment [26]. The
coMET package [27] was used to create a regional plot
for visualization of the association P values. To correct
for multiple comparisons, False Discovery Rate (FDR) q-
values [28] were calculated for each cognitive measure
across the 48 CpG sites, and FDR q < 0.1 was considered
significant. For significant associations, models further
controlling for hypertension, diabetes, BMI, and current
smoking were constructed to test potential confounding
by these cognition risk factors. Similarly, in participants
with available data for WMH (N = 232), we further adjusted
the significant associations for hypertension and WMH.
To test the potential confounding effect of the APOE
ε4 allele on the association between methylation and cog-
nition, a subset analysis was conducted among people
with available genotype data (N = 247). For Models 1 and
2, ε4 carrier status was added as an adjustment variable.
Only CpG sites showing significant association with cog-
nitive measures in the primary analysis (FDR q < 0.1) were
further evaluated in the subset analysis. Associations with
P < 0.05 were considered to remain significant in the sub-
set analysis.
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For cognitive measures that showed significant associ-
ations with CpG sites after accounting for ε4 (P < 0.05 in
the subset analysis), we quantified the percent variation
in the cognitive measure explained by methylation. We
first constructed a full model that included all of the sig-
nificant CpG sites, plus age, sex, and ε4 carrier status.
We then compared this full model to a reduced model
that excluded the CpG sites, and calculated the change
in R2. We repeated this analysis including education in
both the full and reduced models.
We also examined education and ε4 as potential modi-
fiers of the effect of methylation on cognitive function.
For the significant CpG sites in the full sample analysis
(FDR q < 0.1), an interaction term between education
and methylation was added to Model 2. Similarly, an
interaction term for ε4 carrier status and methylation
was further added to each of the regression models per-
formed in the subset analysis. Interactions with P < 0.05
were considered significant.
Sensitivity analyses
People with a previous stroke or prodromal dementia
may have cognitive changes or methylation alternations
that are distinct from those of non-pathological cogni-
tive aging. We used results from the Mini–Mental State
Examination (MMSE), a screening tool for dementia
[18], to identify participants that may be in the early
stages of dementia. In order to assess whether people
with previous stroke or preliminary evidence of demen-
tia influenced the estimated association between methy-
lation and cognition, 46 participants with stroke history
and/or with an MMSE score of 23 or less [18] were fur-
ther excluded from the full sample, and the primary ana-
lysis was repeated on the significant CpG sites in the
remaining 243 participants.
Moreover, since the APOE ε2 allele has been previously
reported to have a protective effect on cognitive function
[29], we also assessed whether the ε2 allele masked the ef-
fect of ε4. To evaluate this, we repeated the subset analysis
in 186 participants who were non-carriers of the ε2 allele.
Associations with P < 0.05 were considered to remain sig-
nificant in the sensitivity analyses.
Methylation correlations across blood and brain
To investigate whether cognition-related methylation
changes identified in this study (FDR q < 0.1) may reflect
underlying methylation changes in the brain, we used two
publically-available databases that compare blood and
brain methylation. The Blood Brain DNA Methylation
Comparison Tool (http://epigenetics.essex.ac.uk/blood-
brain/) [30] includes methylation levels in whole blood
and four brain regions (prefrontal cortex (PFC), entorhinal
cortex (EC), superior temporal gyrus (STG), and cerebel-
lum (CER)) in N = 71–75 matched samples from
individuals archived in the MRC London Neurodegener-
ative Disease Brain Bank. This sample includes both
neuropathologically unaffected controls and individuals
with variable levels of neuropathology. The Blood-Brain
Epigenetic Concordance database (BECon; https://red-
gar598.shinyapps.io/BECon/) [31] includes methylation
levels in blood and three cortical regions (Broadmann
area 10 (BA10), prefrontal cortex; Broadmann area 7
(BA7), parietal cortex; and Broadmann area 20 (BA20)
temporal cortex) from 16 individuals ranging from 15




Sample characteristics are shown in Table 1. The range
of age at cognitive testing in the full sample was 45 to
85 years (mean = 67), and 71.6% of the participants were
female. Participants were relatively evenly distributed
across three education levels. Participant characteristics
were not significantly different between the full sample
and the subset sample (T-test or χ 2 test P > 0.05 for all
characteristics). The APOE ε4 allele frequency in the
subset sample (0.23) was consistent with previous
findings in African Americans [32, 33].
Methylation pattern in the APOE genomic region
The mean methylation level (%) at each CpG site within
the PVRL2-TOMM40-APOE-APOC1 region is shown in
Fig. 1. The variability in methylation levels across indi-
viduals was different between CpG sites, with standard
deviation ranging from 0.7 to 7%. The mean methylation
levels of the 13 CpGs in the APOE gene were consistent
with previous observations [13]. Specifically, the first
three and the last four CpGs had relatively high methyla-
tion (> 50%), while the six CpG sites between them had
relatively low methylation (< 50%). Among all 48 CpG
sites in our study, 15 had relatively high methylation
(> 50%), and 23 were located in promoter regions. The
CpG sites in the promoter regions of PVRL2 and
TOMM40 had relatively low methylation (< 50%), while
the mean methylation levels of CpG sites in the APOE
and the APOC1 promoter regions were more variable.
Methylation levels were positively correlated for 82% of
the pairs of CpG sites. For all pairs, Pearson correlation
coefficients (r) ranged from − 0.15 to 0.59 (Fig. 2).
Association between methylation and cognitive function
We evaluated the association between DNA methylation
of the 48 CpG sites in the PVRL2-TOMM40-APOE-
APOC1 genomic region and cognitive measures in the
full analysis sample (N = 289). We observed significant
inverse associations (FDR q < 0.1) between methylation
levels of eight CpG sites and delayed recall (Table 2),
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Table 1 Characteristics of African Americans from the GENOA study with cognitive and DNA methylation dataa
Full analysis sampleb Subset samplec
(N = 289) (N = 247)
Age (years) 67.2 (7.1) 67.4 (6.8)
Sex (female) 207 (72%) 183 (74%)
Education Less than high school degree 95 (33%) 83 (34%)
High school degree / GED 81 (28%) 68 (27%)
Beyond high school degree 113 (39%) 96 (39%)
Body mass index (BMI, kg/m2) 30.9 (6.0) 30.9 (6.1)
Current smoker 34 (12%) 29 (12%)
Diabetes 85 (29%) 70 (28%)
Hypertension 241 (83%) 205 (83%)
White matter hyperintensity (WMH, cm3) 12.0 (14.2) 11.9 (13.6)
APOE ε4 carrier N/A 102 (41%)
APOE ε2 carrier N/A 60 (24%)
Processing speed (DSST, symbols)d 30.6 (13.2) 30.4 (13.2)
Category fluency (Animal Naming, words)d 14.2 (4.4) 14.0 (4.2)
Letter fluency (FAS, words)d 28.2 (11.5) 28.1 (11.5)
Learning (RAVLT, words)d 38. 5 (9.7) 38.5 (9.5)
Delayed recall (RAVLT, words)d 6.1 (3.6) 6.2 (3.6)
Concentration effectiveness (SCWT, items)d 20.5 (9.1) 20.4 (8.9)
Global cognitive function − 0.12 (0.95) − 0.17 (0.94)
aMean (standard deviation) or n (%) are presented
bIn the full sample, sample sizes for the cognitive measures range from 243 to 289. A total of 232 participants had data for WMH
cSubset sample consists of subjects with available genotype data
dValues of cognitive scores are the numbers of symbols, words, or items completed within certain time limits as required by each test. For additional details, see
Smith et al. [19]
Fig. 1 Methylation pattern in the APOE region. DNA methylation level (%) is represented by the mean β value multiplied by 100 for each of the
48 CpG sites in the PVRL2-TOMM40-APOE-APOC1 region, adjusted for batch effects and white blood cell proportions (N = 289). Error bars represent
the standard deviation of methylation level at each CpG site. CpG sites marked with an asterisk (*) are in promoter regions (within 1.5 kb before
the transcription start site of the gene)
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including three CpGs in PVRL2 (cg26717215, cg08583001,
and cg11670000), two in TOMM40 (cg22024783 and
cg12271581) and three in APOE (cg04406254, cg01032398,
and cg18768621). All eight CpGs are located in either CGIs
or CGI shelves, and six CpGs are in promoter regions of
the three aforementioned genes. The association P values
for delayed recall on a -log10 scale according to the
chromosomal positions of CpG sites, as well as the correla-
tions among the tested CpG sites, are shown in a regional
plot (Fig. 2). Among the eight CpG sites, methylation
levels of the two CpGs in TOMM40 (cg22024783 and
cg12271581) were moderately correlated (Pearson r = 0.55),
and both were correlated with APOE cg18768621 (Pearson
r = 0.35 for cg22024783, Pearson r = 0.41 for cg12271581)
and PVRL2 cg11670000 (Pearson r = 0.31 for cg22024783,
Pearson r = 0.30 for cg12271581). The correlations among
the other four CpGs were weak (r < 0.3).
After further adjustment for education, the estimated
effect of methylation was mildly attenuated for six of the
eight CpG sites, except for PVRL2 cg08583001 and
TOMM40 cg22024783, where effect estimates increased;
six of the eight CpG sites remained significantly associ-
ated with delayed recall (FDR q < 0.1), with the exception
of PVRL2 cg11670000 (FDR q = 0.120) and TOMM40
cg12271581 (FDR q = 0.121) (Table 2). All associations
remained significant in models further controlling for
hypertension and WMH, as well as in models further
controlling for hypertension, diabetes, BMI and current
smoking (P < 0.05, data not shown). The methylation
levels of the eight CpG sites were also inversely associated
with learning and global cognitive function, adjusted for
age, sex, and education; however, the associations were
not significant after correction for multiple testing (data
not shown). No associations between CpG methylation
Fig. 2 Regional plot of the association between delayed recall and DNA methylation in the PVRL2-TOMM40-APOE-APOC1 region. The top panel
shows -log10 (P value) for the associations between methylation and delayed recall, adjusting for age and sex, according to chromosomal
positions. Significant associations (FDR q < 0.1) are shown in red. The middle panel shows the locations of the genes (Ensembl Genes) and CpG
Islands (CG Islands, from UCSC Genome Browser) in this region. The lower panel shows the correlation in DNA methylation levels among the 48
CpG sites in this region
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and any of the other cognitive measures were significant
after multiple testing correction (data not shown).
When we repeated the analysis for the eight significant
CpG sites in the subset sample with available genotypes
(N = 242), all eight CpG sites remained significant at
P < 0.05, except for APOE cg04406254 with a marginal
significance (P = 0.05), and effect estimates for some
CpGs were slightly attenuated after adjustment for APOE
ε4 carrier status (Additional file 1: Table S1). Together the
eight CpG sites explained an additional 9.1% of the vari-
ance in delayed recall after accounting for age, sex and
APOE ε4, and 8.7% when further adjusted for education.
Education and APOE ε4 carrier status as effect modifiers
A significant interaction was observed between PVRL2
cg08583001 and education on delayed recall (P for inter-
action = 0.0046), adjusted for age and sex. Figure 3
shows predicted delayed recall scores calculated for the
average age and sex distribution in the full analysis
sample (N = 282), and compared between the 10th and
90th percentiles of methylation at PVRL2 cg08583001,
by education level. The negative effect of increased
PVRL2 cg08583001 methylation on delayed recall was
only significant in those with education beyond a high
school degree. However, for participants with high school
degree/GED or less, there was no significant association
between methylation and delayed recall, as demonstrated
by the overlap between the 95% confidence intervals of
predicted delayed recall scores for the 10th and the 90th
percentiles of methylation. This interaction remained sig-
nificant (P for interaction < 0.05) after further controlling
for hypertension and WMH, as well as after controlling
for hypertension, diabetes, BMI and current smoking (data
not shown).
In the subset analysis for individuals with genotype in-
formation (N = 242), a significant interaction was also
observed between TOMM40 cg22024783 and APOE ε4
carrier status (P for interaction = 0.013) on delayed re-
call, adjusted for age and sex. Figure 4 shows predicted
delayed recall scores calculated for the average age and
sex distribution in the subset sample, and compared be-
tween the 10th and 90th percentiles of methylation at
PVRL2 TOMM40 cg22024783, by APOE ε4 carrier status.
The negative effect of increased TOMM40 cg22024783
methylation on delayed recall was only observed for APOE
ε4 carriers, but not for non-carriers. Adjusting for edu-
cation did not substantively change the results shown
in Fig. 4. This interaction remained significant (P for
interaction < 0.05) after further controlling for hypertension
and WMH, and after further controlling for hypertension,
diabetes, BMI and current smoking (data not shown).
Sensitivity analyses
All eight CpG sites significantly associated in the primary
analysis remained at least nominally significantly associ-
ated with delayed recall (P < 0.05) after excluding people
with stroke history or MMSE ≤23 (Additional file 2:
Table S2). In the sensitivity analysis that excluded
APOE ε2 allele carriers, results were largely consistent
with the analysis that included ε2 allele carriers, al-
though a few CpGs lost significance due to the reduced
sample size (Additional file 3: Table S3). Given the
similarity of results before and after excluding those
with previous stroke, preliminary evidence of dementia,
Fig. 3 Interaction between PVRL2 cg08583001 and education on delayed recall. Predicted delayed recall scores were calculated based on the
average age and sex distribution in the full analysis sample (N = 282), and compared between the 10th and the 90th percentiles of methylation
at PVRL2 cg08583001 by education level. Error bars denote the 95% confidence interval for each predicted delayed recall score
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and/or the ε2 allele, it is likely that these factors did not
substantively influence the analysis findings.
Methylation correlations across blood and brain
Correlation between methylation levels in the blood and
brain tissue for the eight CpGs associated with delayed
recall (FDR q < 0.1) based on data from publically-available
databases is shown in Additional file 4: Figure S1 and
Additional file 5: Figure S2. Results from both databases
show that overall methylation levels are relatively consist-
ent across the tissue types (Additional file 4: Figure S1 and
Additional file 5: Figure S2 (panel 1)). That is, CpG sites
that are highly methylated (> 50% methylation) in blood
are also highly methylated in multiple brain regions. Inter-
individual variations tended to be positively correlated be-
tween blood and brain for most of the significant CpG sites
evaluated. Correlations between blood and the four evalu-
ated regions using the Blood Brain DNA Methylation
Comparison Tool ranged from − 0.275 to 0.312, but 23 of
the 32 tested correlations (72%) were positive (Additional
file 4: Figure S1). Using BECon, correlations between blood
and the three evaluated regions ranged from − 0.56 to 0.45,
but 15 out of the 24 tested correlations (63%) were positive
(Additional file 5: Figure S2 (panel 2)).
Discussion
While previous studies have suggested that epigenetic
modifications may contribute to AD [14, 15], very little
is known about the association between DNA methyla-
tion and age-related cognitive impairment in those with-
out dementia. To our knowledge this study is the first
assessment of the association between DNA methylation
and cognitive function in a non-AD population. Studies
such as this may enhance understanding of the epigen-
etic profile for cognitive aging as well as contribute to
earlier and novel treatment or intervention strategies for
aging-related impairments in cognitive function.
We assessed DNA methylation in the PVRL2-TOMM40-
APOE-APOC1 genomic region, which comprises a moder-
ate to strong linkage disequilibrium (LD) block. Many SNPs
in this region, in all four of the genes, have been found to
be associated with AD or cognitive impairment [4–10]. It is
still unclear whether the majority of the detected associa-
tions between the three neighboring genes and cognitive
impairment are independent of APOE genetic variation or
driven at least partially by LD with APOE [5, 6]. Each of the
three neighboring genes encodes proteins with biological
functions that could plausibly influence cognitive function
or AD pathogenesis [9]. Specifically, PVRL2 encodes a cell
surface protein involved in the entry activity of herpes sim-
plex virus type 1 (HSV-1) [34, 35]. HSV-1 DNA has been
detected in the brains of both healthy elderly and AD cases
[36, 37], and has been shown to be a risk factor for AD in
ε4 carriers [38]. TOMM40 encodes a pore subunit of the
mitochondrial outer membrane protein translocator,
and mitochondrial dysfunction plays an important role
in the early pathology of AD [39, 40]. APOC1 encodes
an apolipoprotein involved in a variety of biological
processes including cholesterol metabolism and neuronal
apoptosis [41].
Previous functional genomic analysis indicated that
genetic variants in this region may have regulatory ef-
fects, and gene expression patterns within the region
may be modulated by a complex transcriptional
Fig. 4 Interaction between TOMM40 cg22024783 and APOE ε4 carrier status on delayed recall. Predicted delayed recall scores were calculated
based on the average age and sex distribution in the subset sample (N = 242), and compared between the 10th and the 90th percentiles of
methylation at TOMM40 cg22024783 by APOE ε4 carrier status. Error bars denote the 95% confidence interval for each predicted delayed recall score
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regulatory structure [42]. The four genes in this region
may be mutually influenced by each other through cis-
elements, supporting the claim that it may be inaccurate
to attribute all of this region’s genetic influences on AD
and cognition to APOE alone [8]. We identified eight
CpG sites in three genes within this genomic region
(PVRL2, TOMM40, and APOE) that had methylation
levels significantly associated with delayed recall. Among
the eight CpG sites, methylation levels of the two CpGs
in TOMM40 (cg22024783 and cg12271581) were moder-
ately correlated, and both were correlated with APOE
cg18768621 and PVRL2 cg11670000. These moderate
correlations provide evidence for the underlying co-
regulation structure in this region, which may be due to
underlying patterns of LD as well as shared response to
environmental stimuli. The remaining four CpG sites
were only weakly correlated (r < 0.3), suggesting that
there may also be a role for more site-specific effects on
cognition and/or gene expression.
While fewer than half of the 48 CpGs we explored are
located in promoter regions, the majority of the signifi-
cant CpGs (six out of eight) are promoter-nested sites
(Table 2), suggesting that the promoter regions of
PVRL2, TOMM40, and APOE may have important epi-
genetic regulatory functions. Also, as shown by the EN-
CODE regulation track on UCSC Genome Browser
(http://genome.ucsc.edu/), signals for common histone
marks including H3K4Me3, H3K4Me1, and H3K27Ac
have been detected in and around the promoters of
these genes, indicating hotspots for histone modification
and chromatin remodeling within these regions. More-
over, all of the significant CpG sites are located in either
CGIs or CGI shelves (Table 2). However, no significant
results were found for APOC1, a gene without a CGI
(Fig. 2). Enriched with high CpG content, CGIs have
important regulatory function, influencing transcription ac-
tivity and local chromatin configuration [43]. In addition,
previous studies have indicated that CGI flanking regions
(both CGI shores and shelves) may also be involved in gene
regulation and disease pathophysiology [44, 45]. While
most of the CGIs in the human genome are nested in pro-
moter regions, the APOE gene is among the gene group
that does not possess a classical promoter CGI, but a 3’-
end CGI in the exon region [46]. A previous study showed
two regions within this 3’-CGI in which AD cases had
lower methylation levels than controls, and the difference
was only significant in brain regions profoundly impacted
by AD pathophysiology (frontal lobe and hippocampus)
[14]. In our study, we found three significant CpGs in the
shelf of the APOE 3’-CGI, but none in the CGI itself. This
is possibly because only three of the 90 CpGs in the
APOE 3’-CGI are present on the Illumina 450K chip,
and the inter-individual variation within the 3’-CGI
has been shown to be low [46]; thus the 48 CpGs
sites analyzed in this study may not necessarily repre-
sent the other unmeasured sites.
Significant associations (FDR q < 0.1) between methy-
lation and cognitive measures were only observed for
delayed recall, but not for any of the other cognitive
measures. Nevertheless, the methylation levels of the
eight CpG sites were also consistently inversely associ-
ated with learning and global cognitive function, and
most of the P values were significant at a nominal level
(P < 0.05), although they became insignificant after cor-
rection for multiple testing. It has been suggested that
DNA methylation has a critical role for maintaining
normal hippocampal function, and may contribute to
age-related changes in synaptic plasticity and memory
function [47, 48]. Moreover, as reported in previous
population studies on cognitive impairment or dementia,
while the APOE ε4 allele has been associated with various
cognitive domains, the strongest association was observed
for memory [29]. Our similar findings on methylation in
the APOE region are in accord with previous studies, indi-
cating that the detrimental effects of APOE and/or other
neighboring genes may be more pronounced on memory
than other cognitive functions.
The effects of methylation in the APOE genomic re-
gion on cognitive function may be mediated by alter-
ations in gene expression. Increased DNA methylation,
especially in promoter regions, often results in repressed
gene expression. DNA methylation may repress gene ex-
pression by either blocking access of transcriptional fac-
tors or recruiting methyl-CpG-binding proteins, which
can induce further histone modifications and altered chro-
matin status [49]. In line with this, data from Encyclopedia
of DNA Elements (ENCODE) consortium suggested a
negative correlation between methylation in the APOE
gene (including the three CpGs showing significance in
our study) and gene expression in multiple cell lines [13].
Previous studies have also shown an association between
down-regulated gene expression in this region and de-
creased cognitive function. For example, lower plasma
level apoE has been reported to be associated with lower
cognitive function [50] and higher risk of dementia [51].
In brain tissue from AD cases, APOE mRNA level was in-
versely associated with pathology load, and a separate
sample of probable AD cases had a 60% decrease in APOE
mRNA level in lymphocytes compared to controls [52]. A
trend of downregulation of TOMM40 expression was also
observed in AD brains as well as blood samples compared
with controls [53]. In line with these findings, our study
also showed that increased methylation in the promoters of
genes in this region is associated with decreased memory
function. However, we did not have the ability to assess the
relationship between methylation and gene expression
levels in this cohort. Future studies on methylation-gene
expression and gene expression-cognition associations, in
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populations both with and without AD, will help validate
the functional effects of methylation in the APOE region.
For the majority of the detected associations between
methylation and delayed recall, adjustment for education
tended to attenuate the estimated effect of methylation,
but the changes were small (Table 2). However, we
found that education level modified the effect of PVRL2
cg08583001 methylation on delayed recall, such that the
deleterious effect of methylation was only present for
individuals with education beyond high school. Addi-
tionally, we found a significant interaction between
TOMM40 cg22024783 and being a carrier of the APOE
ε4 allele. Overall, these findings suggest that the methy-
lation effect is modified by both genetic factors as well
as environmental factors. The underlying biological
pathways for these interactions will be an important
area of future research.
Our study showed that eight CpG sites in the PVRL2-
TOMM40-APOE-APOC1 genomic region explained
nearly 10 % of the variance in the delayed recall
measure, after accounting for age, sex, education, and
APOE ε4. Similarly, a previous epigenome-wide associ-
ation study (EWAS) reported that 71 significant CpGs
together have a higher explanatory power (28.7%) for
AD pathologic burden than known genetic risk variants
(13.9%) [54]. These findings highlight the important
role of epigenetic mechanisms in phenotypic diversity
and disease pathophysiology. Future work expanding to
other gene regions known to be associated with cogni-
tive impairment, as well as the regions discovered in
EWAS studies for AD [3] will improve our understand-
ing of the epigenetic structure of cognitive function.
Our study has several strengths. To our knowledge,
this is the first study to assess the association between
APOE methylation and cognitive function in a population-
based cohort of older adults without diagnosed dementia.
In addition, our research was conducted in African
Americans, an under-studied population with high
prevalence of dementia and high allele frequency of
APOE ε4 [33]. Furthermore, with rich cognitive mea-
sures, we were able to assess methylation associations
with multiple cognitive domains as well as global cogni-
tive function. Last, while most studies have only fo-
cused on the APOE gene, we also evaluated DNA
methylation in the entire LD block surrounding APOE,
providing new insights into the epigenetic profiles of
this genomic region.
This study also has limitations. First, although the
GENOA cohort has substantially more African Americans
than previous epigenetic studies of the APOE region and
cognition, the relatively small sample size of participants
with both methylation and cognitive measures limited our
ability to examine additional regions across the genome.
Second, our findings in blood leukocytes provide only
limited information on the potential underlying patho-
logical processes in the brain. Recently, it was shown that
blood and brain methylation patterns may be quite dis-
tinct, and that inferences may not hold across these tissues
[55, 56]. Nevertheless, for the eight significant CpGs de-
tected in our study, consistent methylation patterns were
found between blood and brain, and inter-individual varia-
tions are positively correlated between blood and brain tis-
sue for the majority of the significant CpGs. While not
without limitations, methylation studies of complex
neurobiological phenotypes in peripheral tissues are es-
sential for identifying biomarkers that precede dementia
and serve as a critical compliment to studies of brain tis-
sue, which can only be obtained after death [30]. Third,
our study has limited implications for causality because
we did not evaluate longitudinal measures of methylation
and cognitive function. Since both methylation and cogni-
tion are dynamic over time, further longitudinal studies are
necessary to investigate how cognitive function changes
with alterations in methylation. Finally, multi-level “omic”
approaches that integrate dense genetic, epigenetic, and
transcriptomic data from this region will improve our
understanding of its genetic influence on cognition and
dementia.
Conclusion
In summary, we identified eight CpG sites in the PVRL2-
TOMM40-APOE-APOC1 genomic region that showed in-
verse association between methylation and delayed recall,
after accounting for age and sex. Education and APOE ε4
modified the effect of methylation at certain CpG sites.
Our findings highlight the important role of epigenetic
mechanisms in influencing cognitive performance, and
suggest that changes in methylation may be fruitful for
early identification of individuals at risk for dementia as
well as potential targets for intervention in asymptomatic
populations.
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